Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 16, Issue 3, Pages 367-379Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.16.3.367
Keywords
angiogenesis; PTK787/ZK 222584; tyrosine kinase inhibitor; vatalanib
Categories
Ask authors/readers for more resources
The licensing of bevacizumab in patients with metastatic colorectal cancer has fuelled research in angiogenesis. Vatalanib (PTK787/ZK 222584), a potent oral tyrosine kinase inhibitor with a selective range of molecular targets, has been extensively investigated and has shown promising results in patients with colorectal cancer in early trials. Dynamic contrast-enhanced MRI has been useful as a pharmacodynamic tool to define the dose that has a biological effect. The primary objectives of the Phase III CONFIRM (Colorectal Oral Novel Therapy for the inhibition of Angiogenesis and Retarding of Metastases in First-line) studies were not met. However, an interesting pre-planned subset analysis in both studies showed that patients with high lactate dehydrogenase derived clinical benefit. Although this type of analysis should always be considered with caution, the Phase III clinical programme of vatalanib is continuing with further innovative studies looking at other indications and schedules for vatalanib.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available